Biotech Values

[DewDiligence]

MYNZ ColoAlert data—too good to be true?

https://www.globenewswire.com/news-release/2023/10/18/2762319/0/en/Mainz-Biomed-Presents-Groundbreaking-Results-of-ColoFuture-Study.html

Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma [pre-cancerous polyps] sensitivity of 80%

MYNZ’s ColoAlert stool-sample diagnostic for CRC, which is similar to EXAS’ Cologuard, is on the market in Europe and certain other countries but is not yet approved in the US.

MYNZ has an enterprise value of only ~$35M, a minuscule fraction of EXAS’ EV.